MedTrace Logo

In-Vehicle Real-Time Cannabis Influenced Driving Detection

NCT07401628 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2026-02-10

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate whether in-vehicle sensor data can be used to detect cannabis-impaired driving in healthy adult recreational cannabis users.

The study aims to assess whether changes in vehicle, driver, and physiological sensor data can distinguish sober driving from cannabis-impaired driving, and how driving performance changes from baseline to approximately 1 to 6 hours after controlled cannabis consumption.

Researchers will compare driving behavior and in-vehicle sensor data from participants who receive controlled cannabis administration with data from a randomized reference group without cannabis exposure, to determine whether cannabis-related impairment driving can be identified on the basis of machine learning.

Participants will complete screening and baseline assessments and drive an instrumented vehicle on a closed test track under sober conditions. Participants assigned to the experimental arm will receive controlled cannabis administration, while participants in the reference arm will receive no intervention. All participants will perform repeated standardized driving sessions over several hours and complete traffic-medical, traffic-psychological, and in-vehicle pre-driving tests. Biological samples and in-vehicle sensor data will be collected throughout the study.

Conditions

  • Driving Under the Influence
  • Cannabis-impaired Driving

Interventions

DRUG

Cannabis (THC)

Participants assigned to the experimental arm receive a single, controlled inhalative administration of cannabis by smoking a THC-containing joint (target dose 0.67 mg THC per kg body weight; cannabis flowers with 15-18% THC).

Sponsors & Collaborators

  • ETH Zurich

    collaborator OTHER

  • University of St.Gallen

    collaborator OTHER

  • University of Bern

    lead OTHER

Principal Investigators

  • Wolfgang Weinmann, Prof. Dr. · Institute for Forensic Medicine, Forensic Chemistry and Toxicology University of Bern

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-01-05
Primary Completion
2026-06-19
Completion
2026-06-19

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07401628 on ClinicalTrials.gov